ASCENTAGE-B (06855) announced that multiple clinical and preclinical advancements of its three drug candidates—olverembatinib (brand name: Nerlynx®), lisaftoclax (brand name: Lisenla®; R&D code: APG-2575), and APG-5918—have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, with one receiving an oral presentation.

This marks the eighth consecutive year that clinical progress on olverembatinib, a first-in-class novel drug developed by ASCENTAGE, has been featured at the ASH Annual Meeting. Additionally, lisaftoclax, another proprietary first-in-class drug, has been selected for the fourth consecutive year, with one of its two clinical updates designated for oral presentation.

Nerlynx® is China’s first approved third-generation BCR-ABL inhibitor. Its commercialization in China is jointly managed by ASCENTAGE and Innovent Biologics. At the upcoming ASH meeting, ASCENTAGE will debut the latest data from the global Phase III POLARIS-1 study, evaluating Nerlynx® combined with low-intensity chemotherapy in newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients. Updates will also include four-year follow-up data from a randomized controlled Phase II registration study on TKI-resistant chronic myeloid leukemia in chronic phase (CML-CP) patients, as well as findings on its efficacy as a second-line treatment for non-T315I mutated CML-CP patients.

Lisaftoclax, an orally available selective Bcl-2 inhibitor developed by ASCENTAGE, demonstrates broad therapeutic potential across hematologic malignancies and solid tumors. It has already been approved in China for treating adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have undergone at least one prior systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. The oral presentation at ASH will highlight updates from the Phase II registration study of lisaftoclax monotherapy in R/R CLL/SLL patients. Additionally, new data from a clinical study combining lisaftoclax with azacitidine (AZA) in treatment-naïve or venetoclax-pretreated myeloid neoplasm patients will be presented as a poster.

The ASH Annual Meeting, one of the largest global conferences in hematology, comprehensively covers research on the etiology and treatment of blood disorders. The 67th ASH Annual Meeting will take place in a hybrid format (in-person and virtual) from December 6–9, 2025, in Orlando, Florida, USA.